United States Oncology Biosimilars Market Report 2017

October 2017 | 104 pages | ID: U51FDC6903BPEN
QYResearch

Abstracts

In this report, the United States Oncology Biosimilars market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Oncology Biosimilars in these regions, from 2012 to 2022 (forecast).

United States Oncology Biosimilars market competition by top manufacturers/players, with Oncology Biosimilars sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• Celltrion Inc.
• Pfizer Inc.
• Biocon
• BIOCAD
• Apotex Inc.
• Dr. Reddy's Laboratories Ltd.
• Sandoz International GmbH
• Intas Pharmaceuticals Ltd.
• STADA Arzneimittel AG
• Teva Pharmaceutical Industries Ltd.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• G-CSF
• Hematopoietic Agents
• Monoclonal Antibodies

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Oncology Biosimilars for each application, including

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Oncology Biosimilars Market Report 2017

1 ONCOLOGY BIOSIMILARS OVERVIEW

1.1 Product Overview and Scope of Oncology Biosimilars
1.2 Classification of Oncology Biosimilars by Product Category
  1.2.1 United States Oncology Biosimilars Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Oncology Biosimilars Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 G-CSF
  1.2.4 Hematopoietic Agents
  1.2.5 Monoclonal Antibodies
1.3 United States Oncology Biosimilars Market by Application/End Users
  1.3.1 United States Oncology Biosimilars Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Retail Pharmacies
  1.3.3 Hospital Pharmacies
  1.3.4 Online Pharmacies
1.4 United States Oncology Biosimilars Market by Region
  1.4.1 United States Oncology Biosimilars Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Oncology Biosimilars Status and Prospect (2012-2022)
  1.4.3 Southwest Oncology Biosimilars Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Oncology Biosimilars Status and Prospect (2012-2022)
  1.4.5 New England Oncology Biosimilars Status and Prospect (2012-2022)
  1.4.6 The South Oncology Biosimilars Status and Prospect (2012-2022)
  1.4.7 The Midwest Oncology Biosimilars Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Oncology Biosimilars (2012-2022)
  1.5.1 United States Oncology Biosimilars Sales and Growth Rate (2012-2022)
  1.5.2 United States Oncology Biosimilars Revenue and Growth Rate (2012-2022)

2 UNITED STATES ONCOLOGY BIOSIMILARS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Oncology Biosimilars Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Oncology Biosimilars Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Oncology Biosimilars Average Price by Players/Suppliers (2012-2017)
2.4 United States Oncology Biosimilars Market Competitive Situation and Trends
  2.4.1 United States Oncology Biosimilars Market Concentration Rate
  2.4.2 United States Oncology Biosimilars Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Oncology Biosimilars Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES ONCOLOGY BIOSIMILARS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Oncology Biosimilars Sales and Market Share by Region (2012-2017)
3.2 United States Oncology Biosimilars Revenue and Market Share by Region (2012-2017)
3.3 United States Oncology Biosimilars Price by Region (2012-2017)

4 UNITED STATES ONCOLOGY BIOSIMILARS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Oncology Biosimilars Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Oncology Biosimilars Revenue and Market Share by Type (2012-2017)
4.3 United States Oncology Biosimilars Price by Type (2012-2017)
4.4 United States Oncology Biosimilars Sales Growth Rate by Type (2012-2017)

5 UNITED STATES ONCOLOGY BIOSIMILARS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Oncology Biosimilars Sales and Market Share by Application (2012-2017)
5.2 United States Oncology Biosimilars Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES ONCOLOGY BIOSIMILARS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 Celltrion Inc.
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Oncology Biosimilars Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Celltrion Inc. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Pfizer Inc.
  6.2.2 Oncology Biosimilars Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Pfizer Inc. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Biocon
  6.3.2 Oncology Biosimilars Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Biocon Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 BIOCAD
  6.4.2 Oncology Biosimilars Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 BIOCAD Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Apotex Inc.
  6.5.2 Oncology Biosimilars Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Apotex Inc. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Dr. Reddy?s Laboratories Ltd.
  6.6.2 Oncology Biosimilars Product Category, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Dr. Reddy?s Laboratories Ltd. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Sandoz International GmbH
  6.7.2 Oncology Biosimilars Product Category, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Sandoz International GmbH Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Intas Pharmaceuticals Ltd.
  6.8.2 Oncology Biosimilars Product Category, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Intas Pharmaceuticals Ltd. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 STADA Arzneimittel AG
  6.9.2 Oncology Biosimilars Product Category, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 STADA Arzneimittel AG Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Teva Pharmaceutical Industries Ltd.
  6.10.2 Oncology Biosimilars Product Category, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview

7 ONCOLOGY BIOSIMILARS MANUFACTURING COST ANALYSIS

7.1 Oncology Biosimilars Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Oncology Biosimilars

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Oncology Biosimilars Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Oncology Biosimilars Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Oncology Biosimilars Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Oncology Biosimilars Sales Volume Forecast by Type (2017-2022)
11.3 United States Oncology Biosimilars Sales Volume Forecast by Application (2017-2022)
11.4 United States Oncology Biosimilars Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Oncology Biosimilars
Figure United States Oncology Biosimilars Market Size (MT) by Type (2012-2022)
Figure United States Oncology Biosimilars Sales Volume Market Share by Type (Product Category) in 2016
Figure G-CSF Product Picture
Figure Hematopoietic Agents Product Picture
Figure Monoclonal Antibodies Product Picture
Figure United States Oncology Biosimilars Market Size (MT) by Application (2012-2022)
Figure United States Sales Market Share of Oncology Biosimilars by Application in 2016
Figure Retail Pharmacies Examples
Table Key Downstream Customer in Retail Pharmacies
Figure Hospital Pharmacies Examples
Table Key Downstream Customer in Hospital Pharmacies
Figure Online Pharmacies Examples
Table Key Downstream Customer in Online Pharmacies
Figure United States Oncology Biosimilars Market Size (Million USD) by Region (2012-2022)
Figure The West Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Oncology Biosimilars Sales (MT) and Growth Rate (2012-2022)
Figure United States Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Oncology Biosimilars Market Major Players Product Sales Volume (MT) (2012-2017)
Table United States Oncology Biosimilars Sales (MT) of Key Players/Suppliers (2012-2017)
Table United States Oncology Biosimilars Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Oncology Biosimilars Sales Share by Players/Suppliers
Figure 2017 United States Oncology Biosimilars Sales Share by Players/Suppliers
Figure United States Oncology Biosimilars Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Oncology Biosimilars Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Oncology Biosimilars Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Oncology Biosimilars Revenue Share by Players/Suppliers
Figure 2017 United States Oncology Biosimilars Revenue Share by Players/Suppliers
Table United States Market Oncology Biosimilars Average Price (USD/Kg) of Key Players/Suppliers (2012-2017)
Figure United States Market Oncology Biosimilars Average Price (USD/Kg) of Key Players/Suppliers in 2016
Figure United States Oncology Biosimilars Market Share of Top 3 Players/Suppliers
Figure United States Oncology Biosimilars Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Oncology Biosimilars Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Oncology Biosimilars Product Category
Table United States Oncology Biosimilars Sales (MT) by Region (2012-2017)
Table United States Oncology Biosimilars Sales Share by Region (2012-2017)
Figure United States Oncology Biosimilars Sales Share by Region (2012-2017)
Figure United States Oncology Biosimilars Sales Market Share by Region in 2016
Table United States Oncology Biosimilars Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Oncology Biosimilars Revenue Share by Region (2012-2017)
Figure United States Oncology Biosimilars Revenue Market Share by Region (2012-2017)
Figure United States Oncology Biosimilars Revenue Market Share by Region in 2016
Table United States Oncology Biosimilars Price (USD/Kg) by Region (2012-2017)
Table United States Oncology Biosimilars Sales (MT) by Type (2012-2017)
Table United States Oncology Biosimilars Sales Share by Type (2012-2017)
Figure United States Oncology Biosimilars Sales Share by Type (2012-2017)
Figure United States Oncology Biosimilars Sales Market Share by Type in 2016
Table United States Oncology Biosimilars Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Oncology Biosimilars Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Oncology Biosimilars by Type (2012-2017)
Figure Revenue Market Share of Oncology Biosimilars by Type in 2016
Table United States Oncology Biosimilars Price (USD/Kg) by Types (2012-2017)
Figure United States Oncology Biosimilars Sales Growth Rate by Type (2012-2017)
Table United States Oncology Biosimilars Sales (MT) by Application (2012-2017)
Table United States Oncology Biosimilars Sales Market Share by Application (2012-2017)
Figure United States Oncology Biosimilars Sales Market Share by Application (2012-2017)
Figure United States Oncology Biosimilars Sales Market Share by Application in 2016
Table United States Oncology Biosimilars Sales Growth Rate by Application (2012-2017)
Figure United States Oncology Biosimilars Sales Growth Rate by Application (2012-2017)
Table Celltrion Inc. Basic Information List
Table Celltrion Inc. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Celltrion Inc. Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Celltrion Inc. Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Celltrion Inc. Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Pfizer Inc. Basic Information List
Table Pfizer Inc. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Pfizer Inc. Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Pfizer Inc. Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Pfizer Inc. Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Biocon Basic Information List
Table Biocon Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Biocon Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Biocon Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Biocon Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table BIOCAD Basic Information List
Table BIOCAD Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure BIOCAD Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure BIOCAD Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure BIOCAD Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Apotex Inc. Basic Information List
Table Apotex Inc. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Apotex Inc. Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Apotex Inc. Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Apotex Inc. Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Dr. Reddy?s Laboratories Ltd. Basic Information List
Table Dr. Reddy?s Laboratories Ltd. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Dr. Reddy?s Laboratories Ltd. Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Dr. Reddy?s Laboratories Ltd. Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Dr. Reddy?s Laboratories Ltd. Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Sandoz International GmbH Basic Information List
Table Sandoz International GmbH Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Sandoz International GmbH Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Sandoz International GmbH Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Sandoz International GmbH Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Intas Pharmaceuticals Ltd. Basic Information List
Table Intas Pharmaceuticals Ltd. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Intas Pharmaceuticals Ltd. Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Intas Pharmaceuticals Ltd. Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Intas Pharmaceuticals Ltd. Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table STADA Arzneimittel AG Basic Information List
Table STADA Arzneimittel AG Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure STADA Arzneimittel AG Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure STADA Arzneimittel AG Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure STADA Arzneimittel AG Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Teva Pharmaceutical Industries Ltd. Basic Information List
Table Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Oncology Biosimilars
Figure Manufacturing Process Analysis of Oncology Biosimilars
Figure Oncology Biosimilars Industrial Chain Analysis
Table Raw Materials Sources of Oncology Biosimilars Major Players/Suppliers in 2016
Table Major Buyers of Oncology Biosimilars
Table Distributors/Traders List
Figure United States Oncology Biosimilars Sales Volume (MT) and Growth Rate Forecast (2017-2022)
Figure United States Oncology Biosimilars Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Oncology Biosimilars Price (USD/Kg) Trend Forecast (2017-2022)
Table United States Oncology Biosimilars Sales Volume (MT) Forecast by Type (2017-2022)
Figure United States Oncology Biosimilars Sales Volume (MT) Forecast by Type (2017-2022)
Figure United States Oncology Biosimilars Sales Volume (MT) Forecast by Type in 2022
Table United States Oncology Biosimilars Sales Volume (MT) Forecast by Application (2017-2022)
Figure United States Oncology Biosimilars Sales Volume (MT) Forecast by Application (2017-2022)
Figure United States Oncology Biosimilars Sales Volume (MT) Forecast by Application in 2022
Table United States Oncology Biosimilars Sales Volume (MT) Forecast by Region (2017-2022)
Table United States Oncology Biosimilars Sales Volume Share Forecast by Region (2017-2022)
Figure United States Oncology Biosimilars Sales Volume Share Forecast by Region (2017-2022)
Figure United States Oncology Biosimilars Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources